Prevalence and Prognosis of Mild Inflammatory Bowel Disease: A Population-Based Cohort Study 1997-2020.

Autor:	Jacobsen HA; Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark. Electronic address: henrik.jacobsen@rn.dk., Karachalia-Sandri A; Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark., Ebert AC; Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark., Allin KH; Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark., Ananthakrishnan AN; Division of Gastroenterology, Crohn's and Colitis Center, Massachusetts General Hospital, Boston, MA, USA., Agrawal M; Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, USA., Ungaro RC; Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, USA., Colombel JF; Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Icahn School of Medicine at Mount Sinai, The Henry D. Janowitz Division of Gastroenterology- Department of Medicine, New York, USA., Larsen L; Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark., Jess T; Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark; Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark.
Jazyk:	angličtina
Zdroj:	Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association [Clin Gastroenterol Hepatol] 2024 Dec 13. Date of Electronic Publication: 2024 Dec 13.
DOI:	10.1016/j.cgh.2024.10.021
Abstrakt:	Background and Aims: The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's disease (CD), are heterogenous diseases ranging from mild to severe. We aimed to describe the prevalence and prognosis of mild IBD in an unselected population-based patient cohort. Methods: We identified all individuals diagnosed with IBD during 1997-2020 in North Denmark (n=4,607). Patients with mild disease, based on treatment history within the first year, were followed for progression to moderate-severe disease, based on a composite outcome of immunomodulators, biologic therapies, IBD-related hospitalization, and/or surgery. We used time-to-event analysis to calculate probabilities of progression based on IBD subtype, age, sex, and duration of mild IBD. Results: Among 2,315 individuals with initial mild IBD, 24.5% (n=474) with UC and 46% (n=174) with CD progressed to moderate-severe disease during follow-up. Of the total IBD population, 52.3% of patients with UC and 86.8% with CD progressed during follow-up. Individuals <18 years at diagnosis were the most likely to progress. The 10-year probability of progressing to moderate-severe UC was 26% after 1 year with mild disease, 19% after 5 years, and 12% after 10 years. The probability of progressing to moderate-severe CD was 53% after 1 year with mild disease, 34% after 5 years, and 33% after 10 years. Conclusions: Approximately one-fourth of individuals with mild UC within one year after diagnosis and half of those with mild CD progressed to moderate-severe disease over time. Young age at diagnosis increased the probability of progression, whereas increasing duration of mild disease decreased the probability. (Copyright © 2024. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu